Pharmaceutical reimbursement assessment committee evaluated whether benefits of anticancer drugs were appropriate
On July 10, pharmaceutical reimbursement assessment committee of Health Insurance Review and Assessment Committee evaluated whether benefits of anticancer drugs were appropriate.
First, Astellas Pharmaceutical Korea's 'Xtandi' passed the committee in the way of reimbursement for risk-sharing. It...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
